摘要
Abstract
Objective To study the clinical effect of bevacizumab combined with FOLFOX regimen in the treatment of patients with advanced colorectal cancer.Methods A total of 148 patients with advanced colorectal cancer who were treated at our hospital from July,2014 to July,2016 were selected as study subjects and were randomly divided into an observation group (74 cases) and a control group (74 cases) with digital method.The control group were treated with FOLFOX and the observation group bevacizumab and FOLFOX.After four cycles of treatment,the clinical efficacy and adverse reactions were compared between the two groups with x 2 test.Results The objective response rate was better in the observation group than in the control group (41.89 ％ vs.14.86 ％),with a statistical difference (x 2=13.297,P=0.000).There were no statistical differences in the incidences of hypertension (22.97％ vs.36.49％),gastrointestinal reactions (22.97％ vs.33.78％),white blood cell decrease (18.92％ vs.28.38％),etc.between these two groups (x 2=3.234,1.834,2.128;P=0.072,0.176,0.145).Conclusions Bevacizumab combined with FOLFOX regimen in the treatment of patients with advanced colorectal cancer has a good clinical effect and high safety,so it is worth being clinically generalized.关键词
贝伐珠单抗/FOLFOX方案/晚期结肠癌/临床疗效Key words
Bevacizumab/FOLFOX regimen/Colon cancer/Survival rate
